Drug Profile
Factor VIII biosimilar - Dong-A ST
Alternative Names: DA-3808Latest Information Update: 19 Nov 2021
Price :
$50
*
At a glance
- Originator Dong-A Pharmaceutical
- Developer Dong-A ST
- Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Haemophilia A
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Haemophilia-A in South Korea (IV, Injection)
- 01 Jan 2012 Dong-A Pharmaceutical's factor VIII biosimilar is available for licensing